InvestorsHub Logo
Followers 21
Posts 2255
Boards Moderated 0
Alias Born 12/05/2021

Re: OncoJock post# 596408

Monday, 05/29/2023 4:32:11 AM

Monday, May 29, 2023 4:32:11 AM

Post# of 636604

The last trial on this list looks quite a bit like the ATL-DC/PD-1 mAb combo trial we all know and love. And it looks like the trial was supposed to finish up this month.

The Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma is in Phase 2 with 40 participants so they will have to go through phase 3 AND show the same OS as NWBO did before it can be close to being called competition.
Als the trial is being conducted in China which will have huge problems getting results recognized in the US/UK/EU

The only serious competition from that list may be from Aivita Biomedical
with 672 participants Autologous Monocytes as Adjunctive Therapy

You can really only speak of any competition after the results of that competitor are published in a medical journal with any standing. So no there are as of today NO competitor s for DCVAXL